Altered xanthine oxidase and N-acetyltransferase activity in obese children

British Journal of Clinical Pharmacology

Volumn 72, Issue 1, 2011, Pages 109-115

  Chiney, Manoj S ^a   Schwarzenberg, Sarah J ^b   Johnson, L'Aurelle A ^a,c  

^a Department of Experimental and Clinical Pharmacology ^*  (United States)

^b Division of Pediatric Gastroenterology   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Caffeine; Drug metabolism; Obesity; Paediatric

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; XANTHINE OXIDASE;

ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; OBESITY; PRIORITY JOURNAL; SCHOOL CHILD; URINALYSIS;

ARYLAMINE N-ACETYLTRANSFERASE; BIOLOGICAL MARKERS; BODY WEIGHT; CAFFEINE; CASE-CONTROL STUDIES; CHILD; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; MODELS, STATISTICAL; OBESITY; XANTHINE OXIDASE;

EID: 79958752412     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03959.x     Document Type: Article

References (44)

1. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991; 49: 536-49.
2. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother 1995; 29: 843-7.
3. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Significant weight reduction in obese subjects enhances carbamazepine elimination. Clin Pharmacol Ther 1992; 51: 501-6.
4. Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 1984; 9: 177-83.
5. Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. Arthritis Rheum 1985; 28: 1117-21.
6. Abernethy DR, Greenblatt DJ. Effects of desmethyldiazepam on diazepam kinetics: a study of effects of a metabolite on parent drug disposition. Clin Pharmacol Ther 1981; 29: 757-61.
7. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359-67.
8. Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, Le Moing JP, Naditch L, Levron JC, Poirier JM. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997; 51: 493-8.
9. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983; 101: 873-80.
10. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-55.
11. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-50.
12. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303: 242-9.
13. Flegal KM, Ogden CL, Yanovski JA, Freedman DS, Shepherd JA, Graubard BI, Borrud LG. High adiposity and high body mass index-for-age in US children and adolescents overall and by race-ethnic group. Am J Clin Nutr 2010; 91: 1020-6.
14. Kennedy MJ, Scripture CD, Kashuba AD, Scott CS, Gaedigk A, Kearns GL. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin Pharmacol Ther 2004; 75: 163-71.
15. Kennedy MJ, Abdel-Rahman SM, Kashuba AD, Leeder JS. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol 2004; 44: 708-14.
16. Mayayo-Sinues E, Fanlo A, Sinues B, Mayayo E, Labarta JI, Garcia de Jalon A, Ferrandez-Longas A. Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children. Eur J Clin Pharmacol 2006; 62: 123-7.
17. Weimann A, Sabroe M, Poulsen HE. Measurement of caffeine and five of the major metabolites in urine by high-performance liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2005; 40: 307-16.
18. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-65.
19. Bendriss EK, Markoglou N, Wainer IW. Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. J Chromatogr B Biomed Sci Appl 2000; 746: 331-8.
20. Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 709: 27-34.
21. Argikar UA, Cloyd JC, Birnbaum AK, Leppik IE, Conway J, Kshirsagar S, Oetting WS, Klein EC, Remmel RP. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Res 2006; 71: 54-63.
22. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009; 121: 21-33.
23. Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology 2009; 73: 658-64.
24. Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, Franklin J, Siegel SE, Seibel NL, Rogers PC, Sather H, Trigg M, Bleyer WA, Carroll WL. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007; 25: 2063-9.
25. Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005; 293: 203-11.
26. Zuccaro P, Guandalini S, Pacifici R, Pichini S, Di Martino L, Guiducci M, Giuliano M, Di Tullio MT, Pettoello Mantovani M. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit 1991; 13: 37-41.
27. Tamsi V, Monostory K, Prough R, Falus A. Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s. Cell Mol Life Sci 2010; 68: 131-46.
28. Xu P, Huecksteadt TP, Hoidal JR. Molecular cloning and characterization of the human xanthine dehydrogenase gene (XDH). Genomics 1996; 34: 173-80.
29. Page S, Powell D, Benboubetra M, Stevens CR, Blake DR, Selase F, Wolstenholme AJ, Harrison R. Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta 1998; 1381: 191-202.
30. Komaki Y, Sugiura H, Koarai A, Tomaki M, Ogawa H, Akita T, Hattori T, Ichinose M. Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways. Pulmonary Pharmacol Ther 2005; 18: 297-302.
31. Conlon MS, Johnson KC, Bewick MA, Lafrenie RM, Donner A. Smoking (active and passive), N-acetyltransferase 2, and risk of breast cancer. Cancer Epidemiol 2010; 34: 142-9.
32. Nothlings U, Yamamoto JF, Wilkens LR, Murphy SP, Park SY, Henderson BE, Kolonel LN, Le Marchand L. Meat and heterocyclic amine intake, smoking, NAT1 and NAT2 polymorphisms, and colorectal cancer risk in the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2098-106.
33. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 2008; 9: 520-31.
34. Burton A, Martin R, Galobardes B, Davey Smith G, Jeffreys M. Young adulthood body mass index and risk of cancer in later adulthood: historical cohort study. Cancer Causes Control 2010; 21: 2069-77.
35. Robinson WR, Poole C, Godley PA. Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control 2008; 19: 793-803.
36. Okasha M, McCarron P, McEwen J, Smith GD. Body mass index in young adulthood and cancer mortality: a retrospective cohort study. J Epidemiol Community Health 2002; 56: 780-4.
37. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.
38. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580.
39. Roe AL, Howard G, Blouin R, Snawder JE. Characterization of cytochrome P450 and glutathione S-transferase activity and expression in male and female ob/ob mice. Int J Obes Relat Metab Disord 1999; 23: 48-53.
40. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37: 8-19.
41. Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. Am J Physiol 1995; 269: E671-8.
42. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-11.
43. Vistisen K, Loft S, Poulsen HE. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. Adv Exp Med Biol 1991; 283: 407-11.
44. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992; 52: 643-58.